Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp's positive outlook is driven by robust growth potential in its plasma and hospital segments, with plasma growth projected at 23.2% and hospital growth at 13.0%, offsetting weaker performance in interventional technologies. The company anticipates significant operating margin improvement and earnings growth fueled by favorable pricing, product mix, and cost reductions, alongside accretive acquisitions. As Haemonetics continues to evolve towards high-growth MedTech, it is positioned to leverage its existing commercial efforts and enhance its profile among key healthcare stakeholders, supporting sustained mid-single-digit revenue growth.

Haemonetics Corp is facing a negative outlook due to anticipated slow revenue growth, projected to fall into the low-single digits driven by declining performance in its Interventional Technologies segment, which has already shown a 6.3% organic sales decline in the first half of FY26. Furthermore, the company’s reliance on its plasma and hospital segments for growth may not offset the challenges posed by increased competition within the blood center space, which is leading to constrained operating margins. Analysts expect that if organic growth continues to slow, it may result in significant multiple compression and further deterioration of the company's earnings performance below consensus estimates.